CA3203273A1 - Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same - Google Patents
Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using sameInfo
- Publication number
- CA3203273A1 CA3203273A1 CA3203273A CA3203273A CA3203273A1 CA 3203273 A1 CA3203273 A1 CA 3203273A1 CA 3203273 A CA3203273 A CA 3203273A CA 3203273 A CA3203273 A CA 3203273A CA 3203273 A1 CA3203273 A1 CA 3203273A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- catalytically active
- variant
- ada2 protein
- active portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100025976 Adenosine deaminase 2 Human genes 0.000 title claims abstract description 499
- 101710142940 Adenosine deaminase 2 Proteins 0.000 title claims abstract description 499
- 238000000034 method Methods 0.000 title claims abstract description 50
- 239000000203 mixture Substances 0.000 title claims abstract description 12
- 101150015374 ADA2 gene Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 85
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims abstract description 52
- 201000010099 disease Diseases 0.000 claims abstract description 52
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 52
- 201000011510 cancer Diseases 0.000 claims abstract description 42
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims abstract description 26
- 229960005305 adenosine Drugs 0.000 claims abstract description 26
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 21
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 21
- 102220607630 Methylmalonyl-CoA mutase, mitochondrial_S262N_mutation Human genes 0.000 claims description 1372
- 150000001413 amino acids Chemical class 0.000 claims description 175
- 239000000539 dimer Substances 0.000 claims description 113
- 102220530054 Testis-expressed protein 10_E179V_mutation Human genes 0.000 claims description 100
- 230000004048 modification Effects 0.000 claims description 98
- 238000012986 modification Methods 0.000 claims description 98
- 102220530094 Linker for activation of T-cells family member 2_R20E_mutation Human genes 0.000 claims description 94
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 65
- 230000027455 binding Effects 0.000 claims description 61
- 230000000694 effects Effects 0.000 claims description 56
- 210000004027 cell Anatomy 0.000 claims description 45
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 45
- 239000008194 pharmaceutical composition Substances 0.000 claims description 44
- 125000000539 amino acid group Chemical group 0.000 claims description 40
- 239000013598 vector Substances 0.000 claims description 36
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 claims description 33
- 238000012217 deletion Methods 0.000 claims description 31
- 230000037430 deletion Effects 0.000 claims description 31
- 230000013595 glycosylation Effects 0.000 claims description 31
- 238000006206 glycosylation reaction Methods 0.000 claims description 31
- 229920001223 polyethylene glycol Polymers 0.000 claims description 28
- 102100036664 Adenosine deaminase Human genes 0.000 claims description 26
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 25
- 239000002202 Polyethylene glycol Substances 0.000 claims description 22
- 230000003197 catalytic effect Effects 0.000 claims description 22
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 claims description 22
- 238000003780 insertion Methods 0.000 claims description 22
- 230000037431 insertion Effects 0.000 claims description 22
- 229920001184 polypeptide Polymers 0.000 claims description 21
- 102000005962 receptors Human genes 0.000 claims description 21
- 108020003175 receptors Proteins 0.000 claims description 21
- 239000000427 antigen Substances 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 239000002246 antineoplastic agent Substances 0.000 claims description 20
- 230000003463 hyperproliferative effect Effects 0.000 claims description 20
- 239000012634 fragment Substances 0.000 claims description 19
- 230000002829 reductive effect Effects 0.000 claims description 19
- 108010003272 Hyaluronate lyase Proteins 0.000 claims description 18
- 102000001974 Hyaluronidases Human genes 0.000 claims description 18
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 18
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 18
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 18
- 229960002773 hyaluronidase Drugs 0.000 claims description 18
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 18
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 17
- 229920000669 heparin Polymers 0.000 claims description 17
- 229960002897 heparin Drugs 0.000 claims description 17
- 102220271762 rs146066553 Human genes 0.000 claims description 17
- 208000035473 Communicable disease Diseases 0.000 claims description 16
- 102220578763 Mapk-regulated corepressor-interacting protein 1_R20D_mutation Human genes 0.000 claims description 16
- 230000003176 fibrotic effect Effects 0.000 claims description 16
- 208000015181 infectious disease Diseases 0.000 claims description 16
- 102220584011 Non-receptor tyrosine-protein kinase TYK2_K26D_mutation Human genes 0.000 claims description 15
- 238000004113 cell culture Methods 0.000 claims description 15
- 230000001965 increasing effect Effects 0.000 claims description 15
- 229920000642 polymer Polymers 0.000 claims description 15
- 229940124597 therapeutic agent Drugs 0.000 claims description 15
- 206010010099 Combined immunodeficiency Diseases 0.000 claims description 14
- 102220493796 HLA class II histocompatibility antigen, DRB1 beta chain_D86A_mutation Human genes 0.000 claims description 14
- 102220532812 Villin-1_D86L_mutation Human genes 0.000 claims description 14
- 102200143877 c.257A>G Human genes 0.000 claims description 14
- 102220355380 c.76A>G Human genes 0.000 claims description 14
- 102220005376 rs33915947 Human genes 0.000 claims description 14
- 102220005405 rs33915947 Human genes 0.000 claims description 14
- 102200071614 rs41331747 Human genes 0.000 claims description 14
- 102220519562 Uroporphyrinogen decarboxylase_D86E_mutation Human genes 0.000 claims description 13
- 239000000710 homodimer Substances 0.000 claims description 13
- 102220053624 rs573892607 Human genes 0.000 claims description 13
- 102220479663 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN_K13E_mutation Human genes 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 108050000203 Adenosine receptors Proteins 0.000 claims description 10
- 102000009346 Adenosine receptors Human genes 0.000 claims description 10
- 102220493797 HLA class II histocompatibility antigen, DRB1 beta chain_D86S_mutation Human genes 0.000 claims description 10
- -1 XTEN sequences Proteins 0.000 claims description 10
- 229920002674 hyaluronan Polymers 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 230000003993 interaction Effects 0.000 claims description 9
- 239000000178 monomer Substances 0.000 claims description 9
- 241000282414 Homo sapiens Species 0.000 claims description 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 8
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 8
- 229940127089 cytotoxic agent Drugs 0.000 claims description 8
- QWTLUPDHBKBULE-UHFFFAOYSA-N 2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]acetic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(O)=O QWTLUPDHBKBULE-UHFFFAOYSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 108010025198 decaglycine Proteins 0.000 claims description 7
- 230000014509 gene expression Effects 0.000 claims description 7
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 claims description 7
- 238000006467 substitution reaction Methods 0.000 claims description 7
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 6
- 229940099552 hyaluronan Drugs 0.000 claims description 6
- 238000002844 melting Methods 0.000 claims description 6
- 230000008018 melting Effects 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 5
- 229930010555 Inosine Natural products 0.000 claims description 5
- SSJJWVREPZVNBF-DGXVIIAXSA-N dG10 Chemical compound C1=NC(C(NC(N)=N2)=O)=C2N1[C@H](O[C@@H]1COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)C[C@@H]1OP(O)(=O)OC[C@@H](O1)[C@@H](O)C[C@@H]1N1C(N=C(NC2=O)N)=C2N=C1 SSJJWVREPZVNBF-DGXVIIAXSA-N 0.000 claims description 5
- 229960003786 inosine Drugs 0.000 claims description 5
- 210000004962 mammalian cell Anatomy 0.000 claims description 5
- 210000001672 ovary Anatomy 0.000 claims description 5
- 102220173368 rs74740454 Human genes 0.000 claims description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- 108010088751 Albumins Proteins 0.000 claims description 4
- 102000009027 Albumins Human genes 0.000 claims description 4
- 229920001734 PEG propionaldehyde Polymers 0.000 claims description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- 230000001093 anti-cancer Effects 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- 108010028584 nucleotidase Proteins 0.000 claims description 4
- 102220027007 rs267607740 Human genes 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 4
- 208000003200 Adenoma Diseases 0.000 claims description 3
- 206010001233 Adenoma benign Diseases 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 101100178973 Homo sapiens SPAM1 gene Proteins 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 208000009956 adenocarcinoma Diseases 0.000 claims description 3
- 201000001256 adenosarcoma Diseases 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 210000001185 bone marrow Anatomy 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 235000014633 carbohydrates Nutrition 0.000 claims description 3
- 210000003679 cervix uteri Anatomy 0.000 claims description 3
- 210000001072 colon Anatomy 0.000 claims description 3
- 210000003128 head Anatomy 0.000 claims description 3
- 210000002216 heart Anatomy 0.000 claims description 3
- 239000000833 heterodimer Substances 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 3
- 210000003739 neck Anatomy 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 102220007514 rs376960358 Human genes 0.000 claims description 3
- 210000003491 skin Anatomy 0.000 claims description 3
- 210000000813 small intestine Anatomy 0.000 claims description 3
- 210000000952 spleen Anatomy 0.000 claims description 3
- 210000001550 testis Anatomy 0.000 claims description 3
- 210000001541 thymus gland Anatomy 0.000 claims description 3
- 210000003932 urinary bladder Anatomy 0.000 claims description 3
- 210000004291 uterus Anatomy 0.000 claims description 3
- 239000003981 vehicle Substances 0.000 claims description 3
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims description 2
- KAWIOCMUARENDQ-UHFFFAOYSA-N 2-(4-chlorophenyl)sulfanyl-n-(4-pyridin-2-yl-1,3-thiazol-2-yl)acetamide Chemical compound C1=CC(Cl)=CC=C1SCC(=O)NC1=NC(C=2N=CC=CC=2)=CS1 KAWIOCMUARENDQ-UHFFFAOYSA-N 0.000 claims description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims description 2
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 2
- 108091023037 Aptamer Proteins 0.000 claims description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 2
- 241000699802 Cricetulus griseus Species 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 241000701022 Cytomegalovirus Species 0.000 claims description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 2
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 claims description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 2
- 229930186217 Glycolipid Natural products 0.000 claims description 2
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 2
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 claims description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 2
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
- 241000192019 Human endogenous retrovirus K Species 0.000 claims description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 2
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 2
- 241000713666 Lentivirus Species 0.000 claims description 2
- 102000003735 Mesothelin Human genes 0.000 claims description 2
- 108090000015 Mesothelin Proteins 0.000 claims description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 102000004338 Transferrin Human genes 0.000 claims description 2
- 108090000901 Transferrin Proteins 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 2
- 239000013059 antihormonal agent Substances 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 150000004648 butanoic acid derivatives Chemical class 0.000 claims description 2
- 239000013068 control sample Substances 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 230000012010 growth Effects 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims description 2
- 230000003308 immunostimulating effect Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 229960005386 ipilimumab Drugs 0.000 claims description 2
- 229940043355 kinase inhibitor Drugs 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 238000012737 microarray-based gene expression Methods 0.000 claims description 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 2
- 229960003301 nivolumab Drugs 0.000 claims description 2
- 230000000174 oncolytic effect Effects 0.000 claims description 2
- 229950004354 phosphorylcholine Drugs 0.000 claims description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 2
- 229950010773 pidilizumab Drugs 0.000 claims description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 102200074035 rs111033550 Human genes 0.000 claims description 2
- 102200016463 rs1449216377 Human genes 0.000 claims description 2
- 102220137369 rs200935960 Human genes 0.000 claims description 2
- 102200006098 rs34968276 Human genes 0.000 claims description 2
- 102200105055 rs4790235 Human genes 0.000 claims description 2
- 102220059224 rs786202312 Human genes 0.000 claims description 2
- 102220151559 rs886060514 Human genes 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 238000007910 systemic administration Methods 0.000 claims description 2
- 239000012581 transferrin Substances 0.000 claims description 2
- 229950007217 tremelimumab Drugs 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 102220496571 MAGUK p55 subfamily member 3_R20A_mutation Human genes 0.000 claims 29
- 102220614785 Calmodulin-3_K11A_mutation Human genes 0.000 claims 27
- 102000055025 Adenosine deaminases Human genes 0.000 claims 9
- 102220612902 Small EDRK-rich factor 1_K13A_mutation Human genes 0.000 claims 4
- 102220467025 Tubulin monoglutamylase TTLL4_K26A_mutation Human genes 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 3
- 101001041117 Homo sapiens Hyaluronidase PH-20 Proteins 0.000 claims 2
- 102100021102 Hyaluronidase PH-20 Human genes 0.000 claims 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 239000002502 liposome Substances 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 102220501037 Kinesin-like protein KIF20A_R366A_mutation Human genes 0.000 claims 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 claims 1
- 102220072395 rs376780156 Human genes 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 239000003550 marker Substances 0.000 abstract description 2
- 235000001014 amino acid Nutrition 0.000 description 168
- 229940024606 amino acid Drugs 0.000 description 124
- 102220542308 60S ribosomal protein L27_R20A_mutation Human genes 0.000 description 68
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 59
- 102220521975 THAP domain-containing protein 1_K11A_mutation Human genes 0.000 description 59
- 230000000875 corresponding effect Effects 0.000 description 43
- 125000005647 linker group Chemical group 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 11
- 102220251280 rs1555165811 Human genes 0.000 description 11
- 102220581881 RNA N6-adenosine-methyltransferase METTL16_K26A_mutation Human genes 0.000 description 10
- 102220507306 Rab11 family-interacting protein 1_K13A_mutation Human genes 0.000 description 10
- 230000007423 decrease Effects 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- NYXRHTOXAYVBMV-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-(2-hydroxyethoxy)acetate;2-methoxyethanol Chemical compound COCCO.OCCOCC(=O)ON1C(=O)CCC1=O NYXRHTOXAYVBMV-UHFFFAOYSA-N 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 102220049003 rs587783671 Human genes 0.000 description 3
- 230000004988 N-glycosylation Effects 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 101000720051 Homo sapiens Adenosine deaminase 2 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 230000017274 T cell anergy Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 102000056434 human ADA2 Human genes 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical compound [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 102220328196 rs1555593511 Human genes 0.000 description 1
- 102220185905 rs61754326 Human genes 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
- C12Y305/04004—Adenosine deaminase (3.5.4.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462063936P | 2014-10-14 | 2014-10-14 | |
| US62/063,936 | 2014-10-14 | ||
| CA3126536A CA3126536C (en) | 2014-10-14 | 2015-10-14 | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3126536A Division CA3126536C (en) | 2014-10-14 | 2015-10-14 | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3203273A1 true CA3203273A1 (en) | 2016-04-21 |
Family
ID=54601993
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3203273A Pending CA3203273A1 (en) | 2014-10-14 | 2015-10-14 | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
| CA2964317A Active CA2964317C (en) | 2014-10-14 | 2015-10-14 | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
| CA3126536A Active CA3126536C (en) | 2014-10-14 | 2015-10-14 | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2964317A Active CA2964317C (en) | 2014-10-14 | 2015-10-14 | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
| CA3126536A Active CA3126536C (en) | 2014-10-14 | 2015-10-14 | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US9969998B2 (enExample) |
| EP (1) | EP3207130B1 (enExample) |
| JP (1) | JP6625627B2 (enExample) |
| KR (1) | KR102122463B1 (enExample) |
| CN (1) | CN108064282A (enExample) |
| AU (2) | AU2015332533B2 (enExample) |
| BR (1) | BR112017007765B1 (enExample) |
| CA (3) | CA3203273A1 (enExample) |
| DK (1) | DK3207130T3 (enExample) |
| EA (1) | EA201700181A1 (enExample) |
| ES (1) | ES2753391T3 (enExample) |
| IL (1) | IL251527B (enExample) |
| NZ (2) | NZ746680A (enExample) |
| PL (1) | PL3207130T3 (enExample) |
| SG (1) | SG11201702934TA (enExample) |
| WO (1) | WO2016061286A2 (enExample) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| US10322949B2 (en) | 2012-03-15 | 2019-06-18 | Flodesign Sonics, Inc. | Transducer and reflector configurations for an acoustophoretic device |
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| US10689609B2 (en) | 2012-03-15 | 2020-06-23 | Flodesign Sonics, Inc. | Acoustic bioreactor processes |
| US9745548B2 (en) | 2012-03-15 | 2017-08-29 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9752113B2 (en) | 2012-03-15 | 2017-09-05 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US10737953B2 (en) | 2012-04-20 | 2020-08-11 | Flodesign Sonics, Inc. | Acoustophoretic method for use in bioreactors |
| US9745569B2 (en) | 2013-09-13 | 2017-08-29 | Flodesign Sonics, Inc. | System for generating high concentration factors for low cell density suspensions |
| SG11201604738TA (en) | 2013-12-12 | 2016-07-28 | Shanghai Hengrui Pharm Co Ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| WO2015105955A1 (en) | 2014-01-08 | 2015-07-16 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| US9744483B2 (en) | 2014-07-02 | 2017-08-29 | Flodesign Sonics, Inc. | Large scale acoustic separation device |
| DK3186281T3 (da) | 2014-08-28 | 2019-06-11 | Halozyme Inc | Kombinationsterapi med et hyaluronan-nedbrydende enzym og en immun-checkpoint-inhibitor |
| JP6625627B2 (ja) | 2014-10-14 | 2019-12-25 | ハロザイム インコーポレイテッド | アデノシンデアミナーゼ−２（ａｄａ２）、その変異体の組成物およびそれを使用する方法 |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| WO2016191283A2 (en) * | 2015-05-22 | 2016-12-01 | University Of Houston System | Enzymatic immunomodulation of solid tumors and user thereof |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| WO2017156483A1 (en) * | 2016-03-11 | 2017-09-14 | University Of Louisville Research Foundation, Inc. | Methods and compositions for treating tumors |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| CN109477103A (zh) * | 2016-06-22 | 2019-03-15 | ProQR治疗上市公司Ⅱ | 单链rna-编辑寡核苷酸 |
| WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| JP7130630B2 (ja) | 2016-09-30 | 2022-09-05 | モレキュラー デバイシーズ， エルエルシー | 最適候補化合物を検出するためのコンピュータ装置およびその方法 |
| WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
| JP2020513248A (ja) | 2016-10-19 | 2020-05-14 | フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． | 音響による親和性細胞抽出 |
| US20180271939A1 (en) * | 2017-03-24 | 2018-09-27 | Milton J. Silverman, JR. | Genetic method to kill cancer cells by suffocation |
| WO2018218137A1 (en) | 2017-05-25 | 2018-11-29 | Leidos, Inc. | Pd-1 and ctla-4 dual inhibitor peptides |
| JP7224650B2 (ja) * | 2017-06-21 | 2023-02-20 | エクスエル‐プロテイン ゲーエムベーハー | タンパク質薬物とｐ／ａペプチドとのコンジュゲート |
| US10391154B2 (en) * | 2017-07-19 | 2019-08-27 | Leadiant Biosciences Ltd. | Compositions and methods for treating or ameliorating fibrosis, systemic sclerosis and scleroderma |
| WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
| WO2019040367A1 (en) * | 2017-08-19 | 2019-02-28 | Ohio State Innovation Foundation | NEW CANCER IMAGING AGENTS BASED ON PEPTIDES |
| CN111556757A (zh) | 2017-10-31 | 2020-08-18 | 西方溶瘤细胞有限公司 | 用于全身递送的平台溶瘤载体 |
| US20200355694A1 (en) * | 2017-11-20 | 2020-11-12 | Konica Minolta, Inc. | Drug Evaluation Method |
| BR112020009889A2 (pt) | 2017-12-14 | 2020-11-03 | Flodesign Sonics, Inc. | acionador e controlador de transdutor acústico |
| KR20200104333A (ko) | 2017-12-28 | 2020-09-03 | 난징 레전드 바이오테크 씨오., 엘티디. | Tigit에 대한 단일-도메인 항체 및 이의 변이체 |
| TW201930349A (zh) * | 2018-01-08 | 2019-08-01 | 大陸商南京傳奇生物科技有限公司 | 多重特異性抗原結合蛋白及其使用方法 |
| TWI802633B (zh) | 2018-01-15 | 2023-05-21 | 大陸商南京傳奇生物科技有限公司 | 針對pd-1之單域抗體及其變異體 |
| AU2018410849B2 (en) | 2018-02-27 | 2025-02-27 | Leidos, Inc. | PD-1 peptide inhibitors |
| WO2019166701A1 (en) * | 2018-03-02 | 2019-09-06 | Turun Yliopisto | Anti-adenosine signaling pathway antibodies conjugated or fused with adenosine deaminase or capable of binding adenosine deaminase |
| US12133884B2 (en) | 2018-05-11 | 2024-11-05 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| CN120775065A (zh) | 2018-07-09 | 2025-10-14 | 普瑞赛格恩公司 | 融合构建体及其使用方法 |
| EP3820520A4 (en) * | 2018-07-12 | 2022-05-11 | Corvus Pharmaceuticals, Inc. | METHODS FOR DETECTING AND TREATING CANCERS HAVING ACTIVATION OF THE ADENOSINE PATHWAY |
| CN118755703A (zh) | 2018-07-25 | 2024-10-11 | 阿特根公司 | 新型透明质酸水解酶突变体和包含其的药物组合物 |
| WO2020023841A1 (en) * | 2018-07-27 | 2020-01-30 | Massachusetts Institute Of Technology | Oligomerized protein-polymer conjugates |
| US12454694B2 (en) | 2018-09-07 | 2025-10-28 | Beam Therapeutics Inc. | Compositions and methods for improving base editing |
| CA3128878A1 (en) * | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Compositions and methods for treating alpha-1 antitrypsin deficiency |
| CN114096666B (zh) | 2019-02-13 | 2025-03-18 | 比姆医疗股份有限公司 | 治疗血红素病变的组合物和方法 |
| JP7586601B2 (ja) * | 2019-02-13 | 2024-11-19 | ビーム セラピューティクス インク． | 遺伝的疾患の治療用を含めアデノシンデアミナーゼ塩基エディターを用いて疾患関連遺伝子を編集する方法 |
| WO2020169577A1 (en) * | 2019-02-19 | 2020-08-27 | Medizinische Universität Wien | New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine |
| CN109988816A (zh) * | 2019-04-12 | 2019-07-09 | 浙江夸克生物科技有限公司 | 一种腺苷脱氨酶测定试剂盒 |
| EP3725323A1 (en) * | 2019-04-17 | 2020-10-21 | Targovax Asa | Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada |
| CN110063970B (zh) * | 2019-04-30 | 2024-09-03 | 上海心脉途医疗科技有限公司 | 与irAE相关的肠道菌群及irAE的治疗和预防方法 |
| AU2020278864A1 (en) * | 2019-05-22 | 2021-12-23 | Toolgen Incorporated | Single base substitution protein, and composition comprising same |
| JP7606471B2 (ja) | 2019-05-22 | 2024-12-25 | レイドス， インコーポレイテッド | Ｌａｇ３結合ペプチド |
| CA3153624A1 (en) * | 2019-09-09 | 2021-03-18 | Beam Therapeutics Inc. | Nucleobase editors and methods of using same |
| CN110607348B (zh) * | 2019-10-14 | 2023-03-10 | 中国医学科学院北京协和医院 | 应用试剂盒和全自动生化仪同时检测两种亚型腺苷脱氨酶同工酶的方法 |
| JP7502861B2 (ja) * | 2019-12-27 | 2024-06-19 | 旭化成株式会社 | 標的物質と両親媒性高分子との複合体の形成反応の反応温度の評価方法 |
| EP4161952A1 (en) | 2020-06-04 | 2023-04-12 | Leidos, Inc. | Immunomodulatory compounds |
| WO2022011256A1 (en) | 2020-07-10 | 2022-01-13 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| US11578102B2 (en) | 2020-07-31 | 2023-02-14 | Leidos, Inc. | LAG3 binding peptides |
| CN120738156A (zh) | 2020-08-07 | 2025-10-03 | 阿特根公司 | 制备重组玻尿酸酶的方法 |
| US11987646B2 (en) | 2020-10-12 | 2024-05-21 | Leidos, Inc. | Immunomodulatory peptides |
| WO2022087484A1 (en) * | 2020-10-23 | 2022-04-28 | Williams Katherine L | Antibodies to coronavirus sars-cov-2 |
| EP4247410A4 (en) | 2020-11-19 | 2025-05-07 | KaliVir Immunotherapeutics, Inc. | ONCOLYTIC IMMUNOTHERAPY BY TUMOR MICROENVIRONMENT REMOVAL |
| CN114350691B (zh) * | 2021-03-05 | 2023-12-08 | 华熙生物科技股份有限公司 | 一种高效表达透明质酸水解酶的基因及其表达方法 |
| CN113416735B (zh) * | 2021-03-17 | 2023-01-31 | 云南中烟工业有限责任公司 | 一种烟草生殖细胞特异高表达基因及应用 |
| JP2024511163A (ja) * | 2021-03-26 | 2024-03-12 | ビーム セラピューティクス インク． | アデノシンデアミナーゼバリアント及びその使用 |
| BR112023022681A2 (pt) | 2021-04-30 | 2024-01-23 | Kalivir Immunotherapeutics Inc | Vírus oncolíticos para expressão modificada de mhc |
| CN113533279B (zh) * | 2021-07-15 | 2022-07-29 | 河北农业大学 | 一种利用荧光二肽纳米微球/核酸适配体检测恩诺沙星的方法 |
| US20240350546A1 (en) * | 2021-08-31 | 2024-10-24 | The Texas A&M University System | Chimeric antigen receptor (car) t cell therapy platform |
| JP2023063852A (ja) * | 2021-10-25 | 2023-05-10 | 株式会社タムロン | 検査装置および情報処理システム |
| US20250295694A1 (en) * | 2021-11-12 | 2025-09-25 | Georgia Tech Research Corporation | Adenosine deaminase 2 compositions and methods for using same |
| CN114965293B (zh) * | 2022-05-10 | 2025-05-09 | 北京理工大学重庆创新中心 | 偏振光谱特征融合的水中氨氮检测方法 |
| WO2023249408A1 (ko) * | 2022-06-22 | 2023-12-28 | (주)알테오젠 | N-말단 및/또는 c-말단이 절단된 가용성 ph20 폴리펩티드 및 이의 용도 |
| CN114935572A (zh) * | 2022-07-25 | 2022-08-23 | 香港科技大学深圳研究院 | 一种基于纳米材料的可视化尿酸检测方法 |
Family Cites Families (266)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2488564A (en) | 1947-06-03 | 1949-11-22 | Orthe Pharmaecutlcal Corp | Preparation of hyaluronidase |
| US2488565A (en) | 1947-06-04 | 1949-11-22 | Ortho Pharma Corp | Preparation of hyaluronidase |
| US2676139A (en) | 1950-09-01 | 1954-04-20 | American Home Prod | Hyaluronidase |
| US2808362A (en) | 1952-05-02 | 1957-10-01 | Armour & Co | Preparation of hyaluronidase |
| US2795529A (en) | 1954-06-17 | 1957-06-11 | American Home Prod | Stabilized hyaluronidase solution containing calcium chloride |
| US2806815A (en) | 1955-04-12 | 1957-09-17 | Ortho Pharma Corp | Stabilized hyaluronidase |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3630200A (en) | 1969-06-09 | 1971-12-28 | Alza Corp | Ocular insert |
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US3847770A (en) | 1972-04-10 | 1974-11-12 | Continental Can Co | Photopolymerizable compositions prepared from beta hydroxy esters and polyitaconates |
| GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
| US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| GB8322007D0 (en) | 1983-08-16 | 1983-09-21 | Wellcome Found | Pharmaceutical delivery system |
| US4952496A (en) | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| US4769027A (en) | 1984-08-15 | 1988-09-06 | Burroughs Wellcome Co. | Delivery system |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5716826A (en) | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
| EP0461200B1 (en) | 1989-02-21 | 1997-01-22 | Washington University | Modified forms of reproductive hormones |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5846951A (en) | 1991-06-06 | 1998-12-08 | The School Of Pharmacy, University Of London | Pharmaceutical compositions |
| US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US5349001A (en) | 1993-01-19 | 1994-09-20 | Enzon, Inc. | Cyclic imide thione activated polyalkylene oxides |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| AU7097094A (en) | 1993-06-01 | 1994-12-20 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5605976A (en) | 1995-05-15 | 1997-02-25 | Enzon, Inc. | Method of preparing polyalkylene oxide carboxylic acids |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| HU218893B (hu) | 1994-03-31 | 2000-12-28 | Amgen Inc. | A megakariocita szaporodás és differenciálódás stimulálására szolgáló módszerek és vízoldható készítmények |
| US5795569A (en) | 1994-03-31 | 1998-08-18 | Amgen Inc. | Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation |
| US20020159979A1 (en) | 1994-06-06 | 2002-10-31 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5747027A (en) | 1995-04-07 | 1998-05-05 | The Regents Of The University Of California | BH55 hyaluronidase |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US7153510B1 (en) | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
| US5756593A (en) | 1995-05-15 | 1998-05-26 | Enzon, Inc. | Method of preparing polyalkyene oxide carboxylic acids |
| FR2735789B1 (fr) | 1995-06-23 | 1997-07-25 | Centre Nat Rech Scient | Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| CA2230758A1 (en) | 1995-09-08 | 1997-03-13 | Genzyme Corporation | Improved aav vectors for gene therapy |
| US7001765B2 (en) | 1996-03-06 | 2006-02-21 | Medigene Ag | Adeno-associated virus vector for boosting immunogenicity of cells |
| US5747322A (en) | 1996-05-09 | 1998-05-05 | The Regents Of The University Of California | Recombinant crab collagenase |
| CA2262405A1 (en) | 1996-08-02 | 1998-02-12 | Bristol-Myers Squibb Company | A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
| US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
| US6258351B1 (en) | 1996-11-06 | 2001-07-10 | Shearwater Corporation | Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| JP2001511648A (ja) * | 1997-02-06 | 2001-08-14 | ヒューマン ジノーム サイエンシーズ，インコーポレイテッド | 樹状細胞由来成長因子 |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| AU751659B2 (en) | 1997-05-02 | 2002-08-22 | Genentech Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| US5990237A (en) | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
| WO1999009139A1 (en) | 1997-08-15 | 1999-02-25 | Rubicon Laboratory, Inc. | Retrovirus and viral vectors |
| CA2304168A1 (en) | 1997-09-19 | 1999-04-01 | The Trustees Of The University Of Pennsylvania | Methods and cell line useful for production of recombinant adeno-associated viruses |
| US20050158273A1 (en) | 1997-09-25 | 2005-07-21 | Harris J. M. | Soluble, degradable polyethylene glycol) derivatives for controllable release of bound molecules into solution |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| US6448369B1 (en) | 1997-11-06 | 2002-09-10 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
| JP4465109B2 (ja) | 1997-12-17 | 2010-05-19 | エンゾン ファーマシューティカルズ，インコーポレーテッド | アミノ及びヒドロキシル含有生物活性剤のポリマープロドラッグ |
| US6180095B1 (en) | 1997-12-17 | 2001-01-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
| US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
| US5965119A (en) | 1997-12-30 | 1999-10-12 | Enzon, Inc. | Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents |
| ES2222689T3 (es) | 1998-03-12 | 2005-02-01 | Nektar Therapeutics Al, Corporation | Derivados del polietilenglicol con grupos reactivos proximales. |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| US6251382B1 (en) | 1998-04-17 | 2001-06-26 | Enzon, Inc. | Biodegradable high molecular weight polymeric linkers and their conjugates |
| US6824766B2 (en) | 1998-04-17 | 2004-11-30 | Enzon, Inc. | Biodegradable high molecular weight polymeric linkers and their conjugates |
| US6153655A (en) | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US6436392B1 (en) | 1998-05-20 | 2002-08-20 | University Of Iowa Research Foundation | Adeno-associated virus vectors |
| AU5039399A (en) | 1998-07-03 | 2000-01-24 | Neles Field Controls Oy | Method and arrangement for measuring fluid |
| WO2000009560A2 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| US6491907B1 (en) | 1998-11-10 | 2002-12-10 | The University Of North Carolina At Chapel Hill | Recombinant parvovirus vectors and method of making |
| EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
| CA2356215C (en) | 1998-12-23 | 2015-11-24 | Pfizer Inc. | Human monoclonal antibodies to ctla-4 |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| KR101155191B1 (ko) | 1999-01-15 | 2012-06-13 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| GB9904582D0 (en) | 1999-02-26 | 1999-04-21 | Nycomed Imaging As | Process |
| US6428968B1 (en) | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
| CZ299516B6 (cs) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
| PE20010288A1 (es) | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
| DE19933288A1 (de) | 1999-07-15 | 2001-01-18 | Medigene Ag | Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung |
| US6461802B1 (en) | 1999-08-02 | 2002-10-08 | Agfa-Gevaert | Adhesive layer for polyester film |
| WO2001014424A2 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| US7241447B1 (en) | 1999-10-07 | 2007-07-10 | University Of Iowa Research Foundation | Adeno-associated virus vectors and uses thereof |
| US6723316B2 (en) | 1999-12-22 | 2004-04-20 | Onyx Pharmaceuticals, Inc. | Herpes simplex virus-1 Glycoprotein C mutants for treating unwanted hyperproliferative cell growth |
| DK1259562T3 (da) | 1999-12-22 | 2006-04-18 | Nektar Therapeutics Al Corp | Sterisk hindrede derivater af vandoplöselige polymerer |
| US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
| US7223593B2 (en) | 2000-01-21 | 2007-05-29 | Biovex Limited | Herpes virus strains for gene therapy |
| US6602498B2 (en) | 2000-02-22 | 2003-08-05 | Shearwater Corporation | N-maleimidyl polymer derivatives |
| US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
| AU2001266557A1 (en) | 2000-04-12 | 2001-10-23 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7306902B2 (en) | 2002-06-28 | 2007-12-11 | Oncolyties Biotech Inc. | Oncolytic viruses as phenotyping agents for neoplasms |
| JP2003533537A (ja) | 2000-05-16 | 2003-11-11 | リポクセン テクノロジーズ リミテッド | タンパク質の誘導体化 |
| NZ522847A (en) | 2000-05-16 | 2004-11-26 | Bolder Biotechnology Inc | Methods for refolding proteins containing free cysteine residues |
| GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
| DK1355919T3 (da) | 2000-12-12 | 2011-03-14 | Medimmune Llc | Molekyler med længere halveringstider, sammensætninger og anvendelser deraf |
| DE60144439D1 (de) | 2000-12-20 | 2011-05-26 | Hoffmann La Roche | Konjugate von erythropoietin (epo) mit polyethylenglykol (peg) |
| TWI246524B (en) | 2001-01-19 | 2006-01-01 | Shearwater Corp | Multi-arm block copolymers as drug delivery vehicles |
| US20020096037A1 (en) | 2001-01-25 | 2002-07-25 | Richard Muller | Color-coded melody text and method of teaching |
| US6888319B2 (en) | 2001-03-01 | 2005-05-03 | Palomar Medical Technologies, Inc. | Flashlamp drive circuit |
| JP4336771B2 (ja) | 2001-03-09 | 2009-09-30 | モルフォシス アーゲー | 血清アルブミン結合部分 |
| US6653103B2 (en) | 2001-03-30 | 2003-11-25 | Wisconsin Alumni Research Foundation | Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides |
| US20040106794A1 (en) | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| ATE500808T1 (de) | 2001-05-11 | 2011-03-15 | Wellstat Biologics Corp | Onkolytische virustherapie |
| IL149701A0 (en) | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
| WO2003005964A2 (en) | 2001-07-11 | 2003-01-23 | University Of Miami | Recombinant vsv for the treatment of tumor cells |
| US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
| JP4758608B2 (ja) | 2001-11-07 | 2011-08-31 | ネクター セラピューティックス | 分枝ポリマーおよびそれらの結合体 |
| US20080194481A1 (en) | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| KR101271635B1 (ko) | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
| JP5424521B2 (ja) | 2001-12-21 | 2014-02-26 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | アルブミン融合タンパク質 |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| EP1487879B1 (en) | 2002-03-01 | 2012-12-26 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
| CN101143221A (zh) | 2002-03-15 | 2008-03-19 | 布赖汉姆妇女医院 | 适合治疗剂全身性递送的中央气道给药 |
| AU2003258060B2 (en) | 2002-03-27 | 2007-07-12 | Baylor College Of Medicine | Potent oncolytic herpes simplex virus for cancer therapy |
| US20030225260A1 (en) | 2002-04-30 | 2003-12-04 | Snyder Richard O. | Production of recombinant AAV virions |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| EP2266601A1 (en) | 2002-06-21 | 2010-12-29 | Wellstat Biologics Corporation | Administration of therapeutic viruses |
| US7087229B2 (en) | 2003-05-30 | 2006-08-08 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| CA2495251C (en) | 2002-08-14 | 2018-03-06 | Macrogenics, Inc. | Fc.gamma.riib-specific antibodies and methods of use thereof |
| AU2003268505A1 (en) | 2002-09-09 | 2004-03-29 | University Of Tennessee Research Foundation | Recombinatant mutants of rhabdovirus and methods of use thereof |
| WO2004022629A2 (en) | 2002-09-09 | 2004-03-18 | Nektar Therapeutics Al, Corporation | Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid |
| KR100980065B1 (ko) | 2002-09-27 | 2010-09-03 | 젠코어 인코포레이티드 | 최적화된 Ｆｃ 변이체 및 그의 제조 방법 |
| NZ521851A (en) | 2002-10-08 | 2005-02-25 | Auckland Uniservices Ltd | Nitroaniline-based unsymmetrical mustard alkylating agents for gene dependent enzyme prodrug therapy |
| AU2003286467B2 (en) | 2002-10-15 | 2009-10-01 | Abbvie Biotherapeutics Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| KR20040040782A (ko) | 2002-11-08 | 2004-05-13 | 선바이오(주) | 신규한 헥사-암 폴리에틸렌글리콜과 유도체 및 그의합성방법 |
| GB2395337B (en) | 2002-11-14 | 2005-12-28 | Gary Michael Wilson | Warning Unit |
| WO2004063351A2 (en) | 2003-01-09 | 2004-07-29 | Macrogenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
| EP2572732A1 (en) | 2003-02-26 | 2013-03-27 | Nektar Therapeutics | Polymer-factor VIII moiety conjugates |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| EP2319857A3 (en) | 2003-03-04 | 2012-06-27 | Yeda Research And Development Co., Ltd. | Pon polypeptides, polynucleotides encoding same and compositions and methods utilizing same |
| SG177008A1 (en) | 2003-03-05 | 2012-01-30 | Halozyme Inc | Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7731974B2 (en) | 2003-03-27 | 2010-06-08 | Ottawa Hospital Research Institute | Mutant vesicular stomatitis viruses and uses thereof |
| CN1788088B (zh) | 2003-03-27 | 2012-09-26 | 渥太华健康研究学会 | 突变的水泡性口炎病毒及其用途 |
| US7610156B2 (en) | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| KR100512483B1 (ko) | 2003-05-07 | 2005-09-05 | 선바이오(주) | 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법 |
| PT2644206T (pt) | 2003-05-23 | 2019-07-10 | Nektar Therapeutics | Derivados de peg contendo duas cadeias de peg |
| WO2005000099A2 (en) * | 2003-06-09 | 2005-01-06 | Genzyme Corporation | BLOOD FACTOR DOMAINS (BFDs) |
| WO2005016974A1 (en) | 2003-08-12 | 2005-02-24 | Lipoxen Technologies Limited | Sialic acid derivatives for protein derivatisation and conjugation |
| ES2874298T3 (es) | 2003-09-30 | 2021-11-04 | Univ Pennsylvania | Clados de virus adenoasociados (AAV), secuencias, vectores que contienen el mismo, y usos de los mismos |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| US7897146B2 (en) | 2003-11-17 | 2011-03-01 | Crusade Laboratories Limited | Treatment using herpes simplex virus |
| GB0326798D0 (en) | 2003-11-17 | 2003-12-24 | Crusade Lab Ltd | Methods for generating mutant virus |
| WO2005049846A2 (en) | 2003-11-17 | 2005-06-02 | Crusade Laboratories Limited | Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer |
| EP2221315A1 (en) | 2003-12-04 | 2010-08-25 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
| ATE554107T1 (de) | 2003-12-19 | 2012-05-15 | Genentech Inc | Als therapeutika geeignete monovalente antikörperfragmente |
| EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| PT1706424E (pt) | 2004-01-12 | 2009-10-01 | Applied Molecular Evolution | Variantes da região fc |
| JP5064037B2 (ja) | 2004-02-23 | 2012-10-31 | ジェネンテック， インコーポレイテッド | 複素環式自壊的リンカーおよび結合体 |
| US7276585B2 (en) | 2004-03-24 | 2007-10-02 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2005118799A1 (en) | 2004-04-15 | 2005-12-15 | Ista Pharmaceuticals, Inc. | Ovine hyaluronidase |
| WO2005116224A2 (en) | 2004-05-18 | 2005-12-08 | Children's Memorial Hospital | Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system |
| US7427396B2 (en) | 2004-06-03 | 2008-09-23 | Genzyme Corporation | AAV vectors for gene delivery to the lung |
| WO2006002394A2 (en) | 2004-06-24 | 2006-01-05 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
| WO2006085967A2 (en) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
| EP2940043A1 (en) | 2004-07-15 | 2015-11-04 | Xencor, Inc. | Optimized fc variants |
| US20070166281A1 (en) | 2004-08-21 | 2007-07-19 | Kosak Kenneth M | Chloroquine coupled antibodies and other proteins with methods for their synthesis |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| EP1819823A2 (en) | 2004-12-01 | 2007-08-22 | Bayer Schering Pharma Aktiengesellschaft | Generation of replication competent viruses for therapeutic use |
| WO2006101692A1 (en) | 2005-03-23 | 2006-09-28 | Pfizer Products Inc. | Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer |
| DK2161336T4 (en) | 2005-05-09 | 2017-04-24 | Ono Pharmaceutical Co | Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies |
| US20070020238A1 (en) | 2005-06-01 | 2007-01-25 | David Baltimore | Method of targeted gene delivery using viral vectors |
| CN105483093A (zh) | 2005-06-23 | 2016-04-13 | 休斯顿大学 | Ⅱ型单纯疱疹病毒突变体在治疗癌症中的用途 |
| RS54271B1 (sr) | 2005-07-01 | 2016-02-29 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1) |
| EP1924596A4 (en) | 2005-08-12 | 2009-07-29 | Human Genome Sciences Inc | ALBUM INFUSION PROTEINS |
| US7943374B2 (en) | 2005-08-21 | 2011-05-17 | Markus Hildinger | Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb |
| US7301003B2 (en) | 2005-08-26 | 2007-11-27 | Enzon Pharmaceuticals, Inc. | Method of preparing polymers having terminal amine groups |
| US7846445B2 (en) | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| US7601798B2 (en) | 2005-10-04 | 2009-10-13 | Enzon Pharmaceuticals, Inc. | Methods of preparing polymers having terminal amine groups using protected amine salts |
| US7989554B2 (en) | 2006-01-10 | 2011-08-02 | Enzon Pharmaceuticals, Inc. | Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid |
| US8048848B2 (en) | 2006-02-03 | 2011-11-01 | Prolor Biotech Ltd. | Long-acting interferons and derivatives thereof and methods thereof |
| KR20090019770A (ko) | 2006-03-13 | 2009-02-25 | 티아이알 테크놀로지 엘피 | 고상 조명 시스템용 적응형 제어 장치 및 전압 결정 방법 |
| WO2007149686A2 (en) | 2006-06-21 | 2007-12-27 | Enzon Pharmaceuticals, Inc. | Stabilized proteins |
| KR20090064453A (ko) | 2006-09-14 | 2009-06-18 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
| CN101534861B (zh) | 2006-09-15 | 2013-10-02 | 安佐制药股份有限公司 | 具有基于位阻酯的生物可降解连接基的聚环氧烷 |
| US20100178684A1 (en) | 2006-12-21 | 2010-07-15 | Woo Savio L C | Transgenic oncolytic viruses and uses thereof |
| JP5442452B2 (ja) | 2007-02-16 | 2014-03-12 | ウイルツ・バイオロジクス・リミテッド | 単純ヘルペスウイルスおよびウイルス複製法 |
| DK2147122T3 (da) | 2007-04-20 | 2014-10-13 | Sigma Tau Rare Diseases S A | Enzymatisk kræftbehandling |
| AU2008242748B2 (en) * | 2007-04-20 | 2013-12-05 | Unikeris Limited | Stable recombinant adenosine deaminase |
| NZ582150A (en) | 2007-06-18 | 2012-08-31 | Msd Oss Bv | Antibodies to human programmed death receptor pd-1 |
| PL2173890T3 (pl) | 2007-06-21 | 2011-07-29 | Univ Muenchen Tech | Białka czynne biologicznie o zwiększonej stabilności in vivo i (lub) in vitro |
| WO2009023270A2 (en) | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
| WO2009111066A1 (en) | 2008-03-06 | 2009-09-11 | Halozyme, Inc. | Large-scale production of soluble hyaluronidase |
| US8313896B2 (en) | 2008-04-04 | 2012-11-20 | The General Hospital Corporation | Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer |
| EP2307033A4 (en) | 2008-05-29 | 2012-06-13 | Gen Hospital Corp | USE OF ONCOLYTIC HERPESVIRUS FOR THE KILLING OF CANCER STEM CELLS |
| CN102203125A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂及其使用方法 |
| CN102165489B (zh) | 2008-09-16 | 2015-11-25 | 赫斯托克斯公司 | 生物标志物表达的可再现量化 |
| HRP20170908T1 (hr) | 2008-12-09 | 2017-09-22 | F. Hoffmann - La Roche Ag | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice |
| NZ593641A (en) | 2008-12-09 | 2013-01-25 | Halozyme Inc | Extended soluble ph20 polypeptides and uses thereof |
| WO2010080909A1 (en) | 2009-01-08 | 2010-07-15 | Yale University | Compositions and methods of use of an oncolytic vesicular stomatitis virus |
| US8680050B2 (en) | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
| US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
| US8716448B2 (en) | 2009-02-03 | 2014-05-06 | Amunix Operating Inc. | Coagulation factor VII compositions and methods of making and using same |
| EP3178835B1 (en) | 2009-02-03 | 2019-04-10 | Amunix Pharmaceuticals, Inc. | Extended recombinant polypeptides and compositions comprising same |
| ES2385251B1 (es) | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
| US20120134977A1 (en) | 2009-06-01 | 2012-05-31 | Yeda Research And Development Co. Ltd. | Prodrugs containing albumin binding probe |
| CN102481331B (zh) | 2009-06-08 | 2017-09-22 | 阿穆尼克斯运营公司 | 葡萄糖调节多肽及其制备和使用方法 |
| CA2764105A1 (en) | 2009-06-08 | 2010-12-16 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
| WO2011028344A2 (en) | 2009-08-25 | 2011-03-10 | Amunix Operating Inc. | Interleukin-1 receptor antagonist compositions and methods of making and using same |
| EP2483301A1 (en) | 2009-10-01 | 2012-08-08 | The United States Of America, As Represented By The Secretary, Department of Health and Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| PT2504364T (pt) | 2009-11-24 | 2017-11-14 | Medimmune Ltd | Agentes de ligação direcionados contra b7-h1 |
| ME02964B (me) | 2009-12-06 | 2018-07-20 | Himerni i hibridni polipeptidi faktora viii-fc, i postupci za njihovu upotrebu | |
| SI2591006T1 (sl) | 2010-07-09 | 2019-10-30 | Bioverativ Therapeutics Inc | Enoverižne molekule, ki jih lahko obdelujemo in polipeptidi izdelani z njihovo uporabo |
| EP2591101B1 (en) | 2010-07-09 | 2018-11-07 | Bioverativ Therapeutics Inc. | Systems for factor viii processing and methods thereof |
| US20130017997A1 (en) | 2010-08-19 | 2013-01-17 | Amunix Operating Inc. | Factor VIII Compositions and Methods of Making and Using Same |
| ES2754394T3 (es) | 2010-09-08 | 2020-04-17 | Chemotherapeutisches Forschungsinstitut Georg Speyer Haus | Receptores de antígenos quiméricos con una región bisagra optimizada |
| MX349622B (es) | 2010-09-08 | 2017-08-07 | Halozyme Inc | Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas. |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2012109387A1 (en) | 2011-02-08 | 2012-08-16 | Halozyme, Inc. | Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia |
| EP2707723B1 (en) | 2011-05-12 | 2016-02-10 | Genentech, Inc. | Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides |
| AU2012290121B2 (en) | 2011-08-01 | 2015-11-26 | Genentech, Inc. | Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors |
| BR112014008849A2 (pt) | 2011-10-20 | 2017-09-12 | Us Health | receptores quiméricos de antígeno anti-cd22 |
| CA2857398A1 (en) | 2011-12-05 | 2013-06-13 | Igenica Biotherapeutics, Inc. | Antibody-drug conjugates and related compounds, compositions, and methods |
| PT3130347T (pt) | 2011-12-30 | 2019-12-10 | Halozyme Inc | Variantes de polipéptidos de ph20, suas formulações e utilizações |
| CA2866612C (en) | 2012-03-08 | 2018-01-16 | Halozyme, Inc. | Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof |
| CA2876730A1 (en) | 2012-07-13 | 2014-01-16 | The Trustees Of The University Of Pennsylvania | Enhancing activity of car t cells by co-introducing a bispecific antibody |
| EP2997134B1 (en) | 2013-05-14 | 2020-06-24 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| JP6307163B2 (ja) | 2013-08-30 | 2018-04-04 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与 |
| SG11201601844TA (en) | 2013-09-13 | 2016-04-28 | Beigene Ltd | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
| US11028143B2 (en) | 2014-01-21 | 2021-06-08 | Novartis Ag | Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules |
| JP6625627B2 (ja) | 2014-10-14 | 2019-12-25 | ハロザイム インコーポレイテッド | アデノシンデアミナーゼ−２（ａｄａ２）、その変異体の組成物およびそれを使用する方法 |
-
2015
- 2015-10-14 JP JP2017519862A patent/JP6625627B2/ja active Active
- 2015-10-14 CA CA3203273A patent/CA3203273A1/en active Pending
- 2015-10-14 AU AU2015332533A patent/AU2015332533B2/en active Active
- 2015-10-14 NZ NZ746680A patent/NZ746680A/en unknown
- 2015-10-14 EA EA201700181A patent/EA201700181A1/ru unknown
- 2015-10-14 SG SG11201702934TA patent/SG11201702934TA/en unknown
- 2015-10-14 CA CA2964317A patent/CA2964317C/en active Active
- 2015-10-14 BR BR112017007765-5A patent/BR112017007765B1/pt active IP Right Grant
- 2015-10-14 DK DK15797486T patent/DK3207130T3/da active
- 2015-10-14 EP EP15797486.6A patent/EP3207130B1/en active Active
- 2015-10-14 NZ NZ730563A patent/NZ730563A/en unknown
- 2015-10-14 KR KR1020177012446A patent/KR102122463B1/ko active Active
- 2015-10-14 CN CN201580067535.3A patent/CN108064282A/zh active Pending
- 2015-10-14 ES ES15797486T patent/ES2753391T3/es active Active
- 2015-10-14 CA CA3126536A patent/CA3126536C/en active Active
- 2015-10-14 WO PCT/US2015/055613 patent/WO2016061286A2/en not_active Ceased
- 2015-10-14 PL PL15797486T patent/PL3207130T3/pl unknown
-
2016
- 2016-04-08 US US15/094,908 patent/US9969998B2/en active Active
-
2017
- 2017-04-03 IL IL251527A patent/IL251527B/en active IP Right Grant
-
2018
- 2018-03-29 US US15/940,803 patent/US11584923B2/en active Active
- 2018-09-25 AU AU2018236742A patent/AU2018236742B2/en active Active
-
2022
- 2022-11-28 US US18/059,135 patent/US20230203470A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3126536C (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
| US12152262B2 (en) | PH20 polypeptide variants, formulations and uses thereof | |
| DK2477603T3 (en) | STABLE CO-DEVELOPMENT OF hyaluronidase and Immunoglobulin, AND METHODS OF USE THEREOF | |
| AU2009333918B2 (en) | Extended soluble PH20 polypeptides and uses thereof | |
| EP2271363B1 (en) | Combinations and methods for subcutaneous administration of immune globulin and hyaluronidase | |
| US20150010529A1 (en) | Thermally stable ph20 hyaluronidase variants and uses thereof | |
| CA2853358A1 (en) | Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof | |
| CN102065886A (zh) | 修饰的透明质酸酶及其在治疗透明质酸相关疾病和病症中的应用 | |
| HK1236572B (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
| HK1236572A1 (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
| EA041896B1 (ru) | Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования | |
| HK1228295A (en) | Ph20 polypeptide variants, formulations and uses thereof | |
| HK1228295A1 (en) | Ph20 polypeptide variants, formulations and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230613 |
|
| EEER | Examination request |
Effective date: 20230613 |
|
| EEER | Examination request |
Effective date: 20230613 |
|
| EEER | Examination request |
Effective date: 20230613 |
|
| EEER | Examination request |
Effective date: 20230613 |
|
| EEER | Examination request |
Effective date: 20230613 |
|
| EEER | Examination request |
Effective date: 20230613 |
|
| EEER | Examination request |
Effective date: 20230613 |
|
| EEER | Examination request |
Effective date: 20230613 |
|
| EEER | Examination request |
Effective date: 20230613 |